SG/CALL/VERTEX PHARMACEUTICALS/480/0.1/17.01.25 | Real-time Boerse Frankfurt Warrants 10:38:21 2024-07-03 EDT | ||
| 3.94 EUR | -5.52% |
|
| Current month | +1.96% | ||
| 1 month | +18.13% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-07-03 | 3.94 | -5.52% |
| 24-07-02 | 4.17 | +3.47% |
| 24-07-01 | 4.03 | -1.47% |
| 24-06-28 | 4.09 | -4.22% |
| 24-06-27 | 4.27 | +0.71% |
Real-time Boerse Frankfurt Warrants
Last update July 03, 2024 at 10:38 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
Société Générale
|
| WKN | SU6E2X |
| ISIN | DE000SU6E2X2 |
| Date issued | 2023-12-29 |
| Strike | 480 $ |
| Maturity | 2025-01-17 (198 Days) |
| Parity | 10 : 1 |
| Emission price | 2.77 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 5.15 € |
|---|---|
| Lowest since issue | 1.5 € |
| Spread | 0.05 € |
| Spread % | 1.24% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
473.8
USD
Average target price
468.3
USD
Spread / Average Target
-1.16%
- Stock Market
- Warrants
- Warrant
